These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

404 related items for PubMed ID: 25333266

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
    Hari Y, Harashima N, Tajima Y, Harada M.
    Oncotarget; 2015 Dec 08; 6(39):41902-15. PubMed ID: 26506422
    [Abstract] [Full Text] [Related]

  • 3. Efficient elimination of cancer cells by deoxyglucose-ABT-263/737 combination therapy.
    Yamaguchi R, Janssen E, Perkins G, Ellisman M, Kitada S, Reed JC.
    PLoS One; 2011 Dec 08; 6(9):e24102. PubMed ID: 21949692
    [Abstract] [Full Text] [Related]

  • 4. Bcl-2 modulation to activate apoptosis in prostate cancer.
    Bray K, Chen HY, Karp CM, May M, Ganesan S, Karantza-Wadsworth V, DiPaola RS, White E.
    Mol Cancer Res; 2009 Sep 08; 7(9):1487-96. PubMed ID: 19737977
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Clitocine induces apoptosis and enhances the lethality of ABT-737 in human colon cancer cells by disrupting the interaction of Mcl-1 and Bak.
    Sun JG, Xiang J, Zeng XL, Li X, Wu P, Fung KP, Liu FY.
    Cancer Lett; 2014 Dec 28; 355(2):253-63. PubMed ID: 25304383
    [Abstract] [Full Text] [Related]

  • 8. Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer.
    Hann CL, Daniel VC, Sugar EA, Dobromilskaya I, Murphy SC, Cope L, Lin X, Hierman JS, Wilburn DL, Watkins DN, Rudin CM.
    Cancer Res; 2008 Apr 01; 68(7):2321-8. PubMed ID: 18381439
    [Abstract] [Full Text] [Related]

  • 9. Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737.
    Oakes SR, Vaillant F, Lim E, Lee L, Breslin K, Feleppa F, Deb S, Ritchie ME, Takano E, Ward T, Fox SB, Generali D, Smyth GK, Strasser A, Huang DC, Visvader JE, Lindeman GJ.
    Proc Natl Acad Sci U S A; 2012 Feb 21; 109(8):2766-71. PubMed ID: 21768359
    [Abstract] [Full Text] [Related]

  • 10. HSP90 inhibitor (NVP-AUY922) enhances the anti-cancer effect of BCL-2 inhibitor (ABT-737) in small cell lung cancer expressing BCL-2.
    Yang H, Lee MH, Park I, Jeon H, Choi J, Seo S, Kim SW, Koh GY, Park KS, Lee DH.
    Cancer Lett; 2017 Dec 28; 411():19-26. PubMed ID: 28987383
    [Abstract] [Full Text] [Related]

  • 11. Bisdemethoxycurcumin Augments Docetaxel Efficacy for Treatment of Prostate Cancer.
    Song Y, Ruan J, Liu S, Yu H.
    Biol Pharm Bull; 2024 Dec 28; 47(8):1437-1446. PubMed ID: 39143009
    [Abstract] [Full Text] [Related]

  • 12. Additive naftopidil treatment synergizes docetaxel-induced apoptosis in human prostate cancer cells.
    Ishii K, Matsuoka I, Kajiwara S, Sasaki T, Miki M, Kato M, Kanda H, Arima K, Shiraishi T, Sugimura Y.
    J Cancer Res Clin Oncol; 2018 Jan 28; 144(1):89-98. PubMed ID: 29098395
    [Abstract] [Full Text] [Related]

  • 13. Docetaxel induces Bcl-2- and pro-apoptotic caspase-independent death of human prostate cancer DU145 cells.
    Ogura T, Tanaka Y, Tamaki H, Harada M.
    Int J Oncol; 2016 Jun 28; 48(6):2330-8. PubMed ID: 27082738
    [Abstract] [Full Text] [Related]

  • 14. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
    Anstee NS, Bilardi RA, Ng AP, Xu Z, Robati M, Vandenberg CJ, Cory S.
    Cell Death Differ; 2019 Jul 28; 26(7):1316-1331. PubMed ID: 30470795
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Combining paclitaxel with ABT-263 has a synergistic effect on paclitaxel resistant prostate cancer cells.
    Wang C, Huang SB, Yang MC, Lin YT, Chu IH, Shen YN, Chiu YH, Hung SH, Kang L, Hong YR, Chen CH.
    PLoS One; 2015 Jul 28; 10(3):e0120913. PubMed ID: 25811469
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737.
    Tahir SK, Yang X, Anderson MG, Morgan-Lappe SE, Sarthy AV, Chen J, Warner RB, Ng SC, Fesik SW, Elmore SW, Rosenberg SH, Tse C.
    Cancer Res; 2007 Feb 01; 67(3):1176-83. PubMed ID: 17283153
    [Abstract] [Full Text] [Related]

  • 20. [Bcl-2 inhibitor ABT-737 enhances the cisplatin-induced apoptosis in breast cancer T47D cells].
    Chen ZJ, Zhang B, Pan SH, Zhao HM, Zhang Y, Feng WH, Li YY, Cao XC.
    Zhonghua Zhong Liu Za Zhi; 2011 Dec 01; 33(12):891-5. PubMed ID: 22340096
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.